User Name Password

back to homepage

Selwyn Resources (SWN.V) - pricing for C$10m financing announced

Comment by Objective Capital , Jul 31, 2007
Questions? Contact our analyst

Selwyn Resources announced it is pricing its C$10m financing at 65 cents per unit. Each unit will consist of a common share and one-half of a share purchase warrant. Each whole warrant will be exercisable at 85 cents over the next two years. The financing, led by Paradigm Capital Inc, includes provision for an over-allotment option of up to C$1m in additional units.

Objective's view:

The new financing gives Selwyn the cash it need to continue its C$25m exploration programme on the Selwyn zinc-lead project. We view this as positive, as much of the current and planned drilling is testing potential high-grade. zones that could materially add to the economics of the project.

In that the unit price is significantly below our base-case valuation the issue is dilutive to our valuation. The net result of the financing would result in a decrease in our valuation from C$0.92 to $C0.89. However, recent assays from the high-grade zones offer an equivalent increase in our valuation.

SIGN UP NOW FOR OBJECTIVE'S STOCK RESEARCH - IT'S FREE!

Objective, Independent, Experienced.
Research you can trust!

Yes! Subscribe me for the latest stock research from Objective.
Email address
My Password
My information:
First Name
Family Name
Title:
Job title:
Job function:
Industry:
I am a:
 
To receive occasional printed reports complete your mailing address:
 
Company Name (if any)
Address
 
 
City
Postcode/Zip
Country

Please Read Objective's Terms of Use.


Balkan Resources (Private) - exploring the Perlati copper deposit in Albania
Oct 09, 2009 | Previous Reports

Scancell Holdings (SCLP.PLUS) - differentiated technology and a focused plan offer ingredients for success
Sep 08, 2009 | Previous Reports

Sofame Technologies (SDW.V) - ambitious, but high risk growth strategy
Aug 24, 2009 | Previous Reports

Soho Resources (SOH.V) - substantial upgrade to total resource
Aug 19, 2009 | Previous Reports

Colt Resources (COLT.CNQ) - Armamar Meda concession showing good potential
Mar 13, 2009 | Previous Reports

NioGold Mining Corp (NOX.V) - valuation robust despite recession and sector meltdown
Mar 10, 2009 | Previous Reports

Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns
Dec 03, 2008 | Previous Reports

Colt Resources (COLT.CNQ) - Armamar Meda concession showing good potential
Mar 13, 2009 | Previous Reports

NioGold Mining Corp (NOX.V) - valuation robust despite recession and sector meltdown
Mar 10, 2009 | Previous Reports

Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns
Dec 03, 2008 | Previous Reports

e-Therapeutics (ETX.L) - ‘success-predictive’ drug discovery may be the key to new treatment horizons
Nov 18, 2008 | Previous Reports

Great Western Minerals (GWG.V) - pressing ahead with mine-to-market strategy
Nov 07, 2008 | Previous Reports

LiDCO (LID.L) - half year results show early signs of being on track
Oct 30, 2008 | Previous Reports

OCCASIONAL PAPERS

Albania - revisting old frontiers
October, 2008

The rise of independent research (IR Magazine)
March, 2006

Presentation to 2005 AIM Conference
Sept 26, 2005

The Role of Sponsored Research
June 22, 2005

Objective's Corporate Brochure
July 01, 2004

Objective Capital's Contact Information
Partnership, sales and product inquiries: marketing@objectivecapital.co.uk
Media services and conference requests: PR@objectivecapital.co.uk
Subscription and customer service issues: service@objectivecapital.co.uk
Comments or opinions on our analysis: analysis@objectivecapital.co.uk

11-12 Tokenhouse Yard, London EC2R 7AS, United Kingdom
ph +44-(0)870-080 2965 fax +44-(0)870-116 0839

About Us | Contact Us
Latest Analysis | Register Free | Archives
 
Copyright 2004 Objective Capital. All rights reserved.
Terms of Use | Privacy Policy | Disclaimer